Project acronym 1toStopVax
Project RNA virus attenuation by altering mutational robustness
Researcher (PI) Marco VIGNUZZI
Host Institution (HI) INSTITUT PASTEUR
Call Details Proof of Concept (PoC), ERC-2016-PoC, ERC-2016-PoC
Summary RNA viruses have extreme mutation frequencies. When a RNA virus replicates, nucleotide mutations are generated resulting in a population of variants. This genetic diversity creates a cloud of mutations that are potentially beneficial to viral survival, but the majority of mutations are detrimental to the virus. By increasing the mutation rate of a RNA virus, viral fitness is reduced because it generates more errors, and attenuates the virus during in vivo infection. Another feature that affects RNA virus fitness is mutational robustness. Mutational robustness is the ability to buffer the negative effects of mutation.
The attenuation of RNA viruses for vaccine production faces problems of genetic instability and reversion to a pathogenic phenotype. The conventional method for attenuation is mostly empirical and specific to the particular RNA virus species.
Hence, it cannot be universally applied to a variety of virus types. We've developed a non-empirical, rational means of attenuating RNA viruses, targeting mutational robustness as modifiable trait.
We demonstrate that mutational robustness of RNA viruses can be modified without changing a virus' physical and biological properties for vaccine production; yet the virus is attenuated as it becomes victim of its naturally high mutation rate. Specifically, the genome of RNA viruses are modified so that a larger proportion of mutations become lethal Stop mutations. Our technology places the virus one step away from these Stop mutations (1-to-Stop). We succeeded in attenuating two RNA viruses from very different viral families, confirming the broad applicability of this approach. These viruses were attenuated in vivo, generated high levels of neutralizing antibody and protected mice from lethal challenge infection.
The proposal now seeks to complete proof of concept studies and develop commercialization strategies to scale up this new technology to preclinical testing with industrial partners.
Summary
RNA viruses have extreme mutation frequencies. When a RNA virus replicates, nucleotide mutations are generated resulting in a population of variants. This genetic diversity creates a cloud of mutations that are potentially beneficial to viral survival, but the majority of mutations are detrimental to the virus. By increasing the mutation rate of a RNA virus, viral fitness is reduced because it generates more errors, and attenuates the virus during in vivo infection. Another feature that affects RNA virus fitness is mutational robustness. Mutational robustness is the ability to buffer the negative effects of mutation.
The attenuation of RNA viruses for vaccine production faces problems of genetic instability and reversion to a pathogenic phenotype. The conventional method for attenuation is mostly empirical and specific to the particular RNA virus species.
Hence, it cannot be universally applied to a variety of virus types. We've developed a non-empirical, rational means of attenuating RNA viruses, targeting mutational robustness as modifiable trait.
We demonstrate that mutational robustness of RNA viruses can be modified without changing a virus' physical and biological properties for vaccine production; yet the virus is attenuated as it becomes victim of its naturally high mutation rate. Specifically, the genome of RNA viruses are modified so that a larger proportion of mutations become lethal Stop mutations. Our technology places the virus one step away from these Stop mutations (1-to-Stop). We succeeded in attenuating two RNA viruses from very different viral families, confirming the broad applicability of this approach. These viruses were attenuated in vivo, generated high levels of neutralizing antibody and protected mice from lethal challenge infection.
The proposal now seeks to complete proof of concept studies and develop commercialization strategies to scale up this new technology to preclinical testing with industrial partners.
Max ERC Funding
150 000 €
Duration
Start date: 2016-09-01, End date: 2018-02-28
Project acronym 3Dmaterials4Energy
Project Hierarchical Inorganic Nanomaterials as Next Generation Catalysts and Filters
Researcher (PI) Taleb Mokari
Host Institution (HI) BEN-GURION UNIVERSITY OF THE NEGEV
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary In the coming few decades, two major global grand challenges will continue to attract the attention of scientists and engineers in academia and industry: achieving clean water and clean energy. This PoC establishes the development of two prototypes, water oxidation catalyst and water purification filter, by creating inexpensive, abundant and versatile hierarchical structures of inorganic nanomaterials (HSINs).
The formation of HSINs has been one of the major obstacles toward achieving a technological progress in various applications. Presently, fabrication of well-defined 3-D structures can be achieved either by photo/electro lithography, assembly, 3D printing or template-mediated methods. Various structures with high quality/yield can be obtained through those techniques, however, these methods suffer from high cost, difficulty of fabrication of free-standing structures, and sometime the throughput is limited. On the other hand, the templated approaches usually are facile, low cost and offer several and complex structures in particular the ones obtained from nature.
Our invention is based on forming the HSINs using fossil templates from nature. We propose to harness the naturally designed morphologies of the fossil templates to rationally form hierarchical structures of nanomaterials. These structures have many advantageous, compared to the current state-of-the-art catalyst and filter, for example high surface area, high porosity, confined space (nano-reactor) and divers functionalities obtained by controlling the chemical composition of the inorganic material shell. Since these properties are important for achieving high performance, we propose HSINs as next generation water oxidation electrocatalyst and water purification filter.
Summary
In the coming few decades, two major global grand challenges will continue to attract the attention of scientists and engineers in academia and industry: achieving clean water and clean energy. This PoC establishes the development of two prototypes, water oxidation catalyst and water purification filter, by creating inexpensive, abundant and versatile hierarchical structures of inorganic nanomaterials (HSINs).
The formation of HSINs has been one of the major obstacles toward achieving a technological progress in various applications. Presently, fabrication of well-defined 3-D structures can be achieved either by photo/electro lithography, assembly, 3D printing or template-mediated methods. Various structures with high quality/yield can be obtained through those techniques, however, these methods suffer from high cost, difficulty of fabrication of free-standing structures, and sometime the throughput is limited. On the other hand, the templated approaches usually are facile, low cost and offer several and complex structures in particular the ones obtained from nature.
Our invention is based on forming the HSINs using fossil templates from nature. We propose to harness the naturally designed morphologies of the fossil templates to rationally form hierarchical structures of nanomaterials. These structures have many advantageous, compared to the current state-of-the-art catalyst and filter, for example high surface area, high porosity, confined space (nano-reactor) and divers functionalities obtained by controlling the chemical composition of the inorganic material shell. Since these properties are important for achieving high performance, we propose HSINs as next generation water oxidation electrocatalyst and water purification filter.
Max ERC Funding
150 000 €
Duration
Start date: 2017-03-01, End date: 2018-08-31
Project acronym AB-SWITCH
Project Evaluation of commercial potential of a low-cost kit based on DNA-nanoswitches for the single-step measurement of diagnostic antibodies
Researcher (PI) Francesco RICCI
Host Institution (HI) UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA
Call Details Proof of Concept (PoC), ERC-2016-PoC, ERC-2016-PoC
Summary "Antibodies are among the most widely monitored class of diagnostic biomarkers. Immunoassays market now covers about 1/3 of the global market of in-vitro diagnostics (about $50 billion). However, current methods for the detection of diagnostic antibodies are either qualitative or require cumbersome, resource-intensive laboratory procedures that need hours to provide clinicians with diagnostic information. A new method for fast and low-cost detection of antibodies will have a strong economic impact in the market of in-vitro diagnostics and Immunoassays.
During our ERC Starting Grant project ""Nature Nanodevices"" we have developed a novel diagnostic technology for the detection of clinically relevant antibodies in serum and other body fluids. The platform (here named Ab-switch) supports the fluorescent detection of diagnostic antibodies (for example, HIV diagnostic antibodies) in a rapid (<3 minutes), single-step and low-cost fashion.
The goal of this Proof of Concept project is to bring our promising platform to the proof of diagnostic market and exploit its innovative features for commercial purposes. We will focus our initial efforts in the development of rapid kits for the detection of antibodies diagnostic of HIV. We will 1) Fully characterize the Ab-switch product in terms of analytical performances (i.e. sensitivity, specificity, stability etc.) with direct comparison with other commercial kits; 2) Prepare a Manufacturing Plan for producing/testing the Ab-switch; 3) Establish an IP strategy for patent filing and maintenance; 4) Determine a business and commercialization planning."
Summary
"Antibodies are among the most widely monitored class of diagnostic biomarkers. Immunoassays market now covers about 1/3 of the global market of in-vitro diagnostics (about $50 billion). However, current methods for the detection of diagnostic antibodies are either qualitative or require cumbersome, resource-intensive laboratory procedures that need hours to provide clinicians with diagnostic information. A new method for fast and low-cost detection of antibodies will have a strong economic impact in the market of in-vitro diagnostics and Immunoassays.
During our ERC Starting Grant project ""Nature Nanodevices"" we have developed a novel diagnostic technology for the detection of clinically relevant antibodies in serum and other body fluids. The platform (here named Ab-switch) supports the fluorescent detection of diagnostic antibodies (for example, HIV diagnostic antibodies) in a rapid (<3 minutes), single-step and low-cost fashion.
The goal of this Proof of Concept project is to bring our promising platform to the proof of diagnostic market and exploit its innovative features for commercial purposes. We will focus our initial efforts in the development of rapid kits for the detection of antibodies diagnostic of HIV. We will 1) Fully characterize the Ab-switch product in terms of analytical performances (i.e. sensitivity, specificity, stability etc.) with direct comparison with other commercial kits; 2) Prepare a Manufacturing Plan for producing/testing the Ab-switch; 3) Establish an IP strategy for patent filing and maintenance; 4) Determine a business and commercialization planning."
Max ERC Funding
150 000 €
Duration
Start date: 2017-02-01, End date: 2018-07-31
Project acronym ACOUSEQ
Project Acoustics for Next Generation Sequencing
Researcher (PI) Jonathan Mark Cooper
Host Institution (HI) UNIVERSITY OF GLASGOW
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary Since completion of the first human genome sequence, the demand for cheaper and faster sequencing methods has increased enormously. This need has driven the development of second-generation sequencing methods, or next-generation sequencing (also known as NGS or high throughput sequencing). The creation of these platforms has made sequencing accessible to more laboratories, rapidly increasing the volume of research, including clinical diagnostics and its use in directing treatment (precision medicine). The applications of NGS are also allowing rapid advances in clinically related fields such as public health and epidemiology. Such developments illustrate why sequencing is now the fastest-growing area in genomics (+23% p.a.). The activity is said to be worth $2.5B this year, and poised to reach ~$9B by 2020. In any workflow, prior to the sequencing reactions, a number of pre-sequencing steps are required, including the fragmentation of the DNA into smaller sizes for processing, size selection, library preparation and target enrichment. This proposal is specifically concerned with this latter area, namely DNA fragmentation – now widely acknowledged across the industry as being the most important technological bottleneck in the pre-sequencing workflow. Our new method for DNA fragmentation – involving using surface acoustic waves will enable sample preparation from lower sample volumes using lower powers. It also has the potential to allow the seamless integration of fragmentation into sequencing instrumentation, opening up the possibility of “sample to answer” diagnostics. In the near term this will enable the implementation of sample preparation pre-sequencing steps within the NGS instruments. In the longer term, our techniques will also enable us to develop methods for field-based DNA sequencing – as may be required for determining “microbial resistance” and informing the treatment of infectious disease in the face of the emergence of drug resistance.
Summary
Since completion of the first human genome sequence, the demand for cheaper and faster sequencing methods has increased enormously. This need has driven the development of second-generation sequencing methods, or next-generation sequencing (also known as NGS or high throughput sequencing). The creation of these platforms has made sequencing accessible to more laboratories, rapidly increasing the volume of research, including clinical diagnostics and its use in directing treatment (precision medicine). The applications of NGS are also allowing rapid advances in clinically related fields such as public health and epidemiology. Such developments illustrate why sequencing is now the fastest-growing area in genomics (+23% p.a.). The activity is said to be worth $2.5B this year, and poised to reach ~$9B by 2020. In any workflow, prior to the sequencing reactions, a number of pre-sequencing steps are required, including the fragmentation of the DNA into smaller sizes for processing, size selection, library preparation and target enrichment. This proposal is specifically concerned with this latter area, namely DNA fragmentation – now widely acknowledged across the industry as being the most important technological bottleneck in the pre-sequencing workflow. Our new method for DNA fragmentation – involving using surface acoustic waves will enable sample preparation from lower sample volumes using lower powers. It also has the potential to allow the seamless integration of fragmentation into sequencing instrumentation, opening up the possibility of “sample to answer” diagnostics. In the near term this will enable the implementation of sample preparation pre-sequencing steps within the NGS instruments. In the longer term, our techniques will also enable us to develop methods for field-based DNA sequencing – as may be required for determining “microbial resistance” and informing the treatment of infectious disease in the face of the emergence of drug resistance.
Max ERC Funding
149 995 €
Duration
Start date: 2017-05-01, End date: 2018-10-31
Project acronym ACTICELL
Project Precision confiner for mechanical cell activation
Researcher (PI) Matthieu PIEL
Host Institution (HI) INSTITUT CURIE
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary In tissues, cells have their physical space constrained by neighbouring cells and extracellular matrix. In the PROMICO ERC project, our team proposed to specifically address the effect of physical confinement on normal and cancer cells that are dividing and migrating, using new pathophysiologically relevant in vitro approaches based on innovative micro-fabrication techniques. One of the devices we developed was meant to quantitatively control two key parameters of the cell environment: its geometry and its surface chemical properties. The main technical breakthrough was achieved using micro-fabricated elastomeric structures bound to a hard substrate (Le Berre Integrative Biology, 2012). The method led to important fundamental discoveries in cell biology (Lancaster Dev Cell 2013, Le Berre PRL 2013, Liu Cell 2015, Raab Science 2016). In part based on our findings, the notion that confinement is a crucial parameter for cell physiology has spread through the cell biology. Based on this, our idea is that cell confinement could be used as a powerfull cell conditioning technology, to change the cell state and offer new opportunities for fundamental research in cell biology, but also in cell therapies and drug screening. However, our current method to confine cells is not adapted to large scale cell conditioning applications, because the throughput and reliability of the device is still too low and because the recovery of cells after confinement remain poorly controlled. It is thus now timely to develop a robust and versatile cell confiner adapted to use in any cell biology lab, in academy and in industry, with no prior experience in micro-fabrication. Achieving this goal involves a complete change of technology compared to the ‘homemade’ PDMS device we have been using so far. We will also perform proofs of concept of its use for its application in cell based therapies, such as cancer immunotherapy, by testing the possibility to mechanically activate dendritic cells.
Summary
In tissues, cells have their physical space constrained by neighbouring cells and extracellular matrix. In the PROMICO ERC project, our team proposed to specifically address the effect of physical confinement on normal and cancer cells that are dividing and migrating, using new pathophysiologically relevant in vitro approaches based on innovative micro-fabrication techniques. One of the devices we developed was meant to quantitatively control two key parameters of the cell environment: its geometry and its surface chemical properties. The main technical breakthrough was achieved using micro-fabricated elastomeric structures bound to a hard substrate (Le Berre Integrative Biology, 2012). The method led to important fundamental discoveries in cell biology (Lancaster Dev Cell 2013, Le Berre PRL 2013, Liu Cell 2015, Raab Science 2016). In part based on our findings, the notion that confinement is a crucial parameter for cell physiology has spread through the cell biology. Based on this, our idea is that cell confinement could be used as a powerfull cell conditioning technology, to change the cell state and offer new opportunities for fundamental research in cell biology, but also in cell therapies and drug screening. However, our current method to confine cells is not adapted to large scale cell conditioning applications, because the throughput and reliability of the device is still too low and because the recovery of cells after confinement remain poorly controlled. It is thus now timely to develop a robust and versatile cell confiner adapted to use in any cell biology lab, in academy and in industry, with no prior experience in micro-fabrication. Achieving this goal involves a complete change of technology compared to the ‘homemade’ PDMS device we have been using so far. We will also perform proofs of concept of its use for its application in cell based therapies, such as cancer immunotherapy, by testing the possibility to mechanically activate dendritic cells.
Max ERC Funding
150 000 €
Duration
Start date: 2017-06-01, End date: 2018-11-30
Project acronym ACTIVEPHANTOM
Project Active Organ Phantoms for Medical Robotics
Researcher (PI) Peer FISCHER
Host Institution (HI) MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary Robot-assisted and minimally invasive medical procedures are impacting medical care by increasing accuracy, reducing cost, and minimizing patient discomfort and recovery times after interventions. Developers of commercial robotic surgical systems and medical device manufacturers look for realistic phantoms that can be used in place of animal experiments or cadavers to test procedures and to train medical personnel. Existing phantoms are either made from hard materials, or they lack anatomical detail, and they are mainly passive and thus unrealistic.
Here, we use recently developed fabrication know-how and expertise within our ERC-funded research to develop the first active artificial urinary tract model that includes a kidney, a bladder, and a prostate. Rapid prototyping is combined with a fabrication step that we have developed to permit the incorporation of active elements, such as a peristaltic system and fluidic valves in the phantom. We have developed smart material composites that reproduce the mechanical and haptic properties, and that give ultrasound contrast indistinguishable from real organs, while permitting anatomical details to be reproduced with a mean error of as little as 500 microns.
Feedback from a major medical device company indicates that ours is a unique phantom with unprecedented accuracy for which there is a market. Within this POC grant we want to develop a complete prototype, and to demonstrate a series of medical interventions on the phantom, including endoscopic diagnostic procedures (cystoscopy and ureterorenoscopy) and endoscopic treatment procedures (laser lithotripsy). The grant will allow us to protect our know-how, identify further markets, and develop a commercialization strategy.
Overall, this project will generate the first active phantom system that permits the testing of surgical instruments and procedures, with a sizeable market potential.
Summary
Robot-assisted and minimally invasive medical procedures are impacting medical care by increasing accuracy, reducing cost, and minimizing patient discomfort and recovery times after interventions. Developers of commercial robotic surgical systems and medical device manufacturers look for realistic phantoms that can be used in place of animal experiments or cadavers to test procedures and to train medical personnel. Existing phantoms are either made from hard materials, or they lack anatomical detail, and they are mainly passive and thus unrealistic.
Here, we use recently developed fabrication know-how and expertise within our ERC-funded research to develop the first active artificial urinary tract model that includes a kidney, a bladder, and a prostate. Rapid prototyping is combined with a fabrication step that we have developed to permit the incorporation of active elements, such as a peristaltic system and fluidic valves in the phantom. We have developed smart material composites that reproduce the mechanical and haptic properties, and that give ultrasound contrast indistinguishable from real organs, while permitting anatomical details to be reproduced with a mean error of as little as 500 microns.
Feedback from a major medical device company indicates that ours is a unique phantom with unprecedented accuracy for which there is a market. Within this POC grant we want to develop a complete prototype, and to demonstrate a series of medical interventions on the phantom, including endoscopic diagnostic procedures (cystoscopy and ureterorenoscopy) and endoscopic treatment procedures (laser lithotripsy). The grant will allow us to protect our know-how, identify further markets, and develop a commercialization strategy.
Overall, this project will generate the first active phantom system that permits the testing of surgical instruments and procedures, with a sizeable market potential.
Max ERC Funding
150 000 €
Duration
Start date: 2017-03-01, End date: 2018-08-31
Project acronym AdaSmartRes
Project Adapter for a commercial grade camera or a smart phone to perform depth resolved imaging
Researcher (PI) Adrian PODOLEANU
Host Institution (HI) UNIVERSITY OF KENT
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary The proposal refers to a patented adapter that can transform a commercial grade digital camera or the camera in a smart phone into a depth resolved imaging instrument. Several adapters will be assembled, making use of optical coherence tomography (OCT) technology protected by some other of PI’s patents. The activity takes advantage of recent progress in commercial grade cameras in terms of their modes of operation as well as in terms of parameters of their devices, such as sensitivity and speed of their photodetector arrays.
Three versions of low cost functional OCT systems will be assembled as proof of concepts responding to needs of three possible markets that can be addressed by such an adapter: 1. En-face depth resolved, high transversal resolution microscope; 2. Fast cross sectioning imager. 3. Swept source volumetric analyser.
Industrial input comes from a company involved in professional eye imaging systems, a company already selling adapters for smart phones to perform medical imaging, a company specialised in digital photographic equipment and a company efficient in prototyping photonics equipment and handling medical images. Clinical input is provided by two specialists in the two highest potential medical imaging markets of the adapter serving ophthalmology and ear, nose and throat speciality.
Summary
The proposal refers to a patented adapter that can transform a commercial grade digital camera or the camera in a smart phone into a depth resolved imaging instrument. Several adapters will be assembled, making use of optical coherence tomography (OCT) technology protected by some other of PI’s patents. The activity takes advantage of recent progress in commercial grade cameras in terms of their modes of operation as well as in terms of parameters of their devices, such as sensitivity and speed of their photodetector arrays.
Three versions of low cost functional OCT systems will be assembled as proof of concepts responding to needs of three possible markets that can be addressed by such an adapter: 1. En-face depth resolved, high transversal resolution microscope; 2. Fast cross sectioning imager. 3. Swept source volumetric analyser.
Industrial input comes from a company involved in professional eye imaging systems, a company already selling adapters for smart phones to perform medical imaging, a company specialised in digital photographic equipment and a company efficient in prototyping photonics equipment and handling medical images. Clinical input is provided by two specialists in the two highest potential medical imaging markets of the adapter serving ophthalmology and ear, nose and throat speciality.
Max ERC Funding
149 300 €
Duration
Start date: 2017-06-01, End date: 2018-11-30
Project acronym AIDViC
Project Antibiotic intracellular delivery via virus-like carriers
Researcher (PI) Giuseppe BATTAGLIA
Host Institution (HI) UNIVERSITY COLLEGE LONDON
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary Taking inspiration from natural carriers, such as viruses, a new technology has been developed in
our laboratories part of an ongoing ERC starting grant project, Molecular Engineering of Virus-like
Carriers (MEViC). We created synthetic viruses using polymers and thus safer materials. They are
able of delivering high payload of specific drugs into cells with no detrimental effect. While testing for
anticancer therapies, we identified a synthetic virus capable of targeting almost exclusively
macrophages. We performed preliminary work showing that this can be successfully applied to
deliver antibiotics to rid of intracellular pathogens. This has now open a completely new possibility
whereas we can expand our technology for the treatment of several infections as well as to contribute
to the ongoing efforts in tackling antibiotic resistance.
Summary
Taking inspiration from natural carriers, such as viruses, a new technology has been developed in
our laboratories part of an ongoing ERC starting grant project, Molecular Engineering of Virus-like
Carriers (MEViC). We created synthetic viruses using polymers and thus safer materials. They are
able of delivering high payload of specific drugs into cells with no detrimental effect. While testing for
anticancer therapies, we identified a synthetic virus capable of targeting almost exclusively
macrophages. We performed preliminary work showing that this can be successfully applied to
deliver antibiotics to rid of intracellular pathogens. This has now open a completely new possibility
whereas we can expand our technology for the treatment of several infections as well as to contribute
to the ongoing efforts in tackling antibiotic resistance.
Max ERC Funding
149 062 €
Duration
Start date: 2017-07-01, End date: 2018-12-31
Project acronym AIM
Project Adaptive Imaging Microscopy
Researcher (PI) Michel Verhaegen
Host Institution (HI) TECHNISCHE UNIVERSITEIT DELFT
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary The project has a goal of starting up a small business producing highly special customizable microscope systems for biomedical research. Microscopic imaging is one of the major drivers of the progress in biomedical and life sciences. The development of novel concepts, addressing the challenges of advanced optical microscopy, represents the front line of scientific research. Modern microscopes are not purely optical devices anymore. They have developed into complex integrated systems, combining optics, mechanics, electronics, feedback control systems, and image processing Many novel concepts of modern microscopy, while very interesting for research, still have to prove the commercial profitability. Such developments can be effectively addressed by start-up companies with a goal of either custom development, production and service of these advanced systems, or development and selling the IP to a larger player.
The major goal of this proposal is the creation of the first commercial optical microscope, the performance of which depends completely on the adaptive optics feedback controls. To prove the feasibility of this approach, we select a highly attractive technical concept of adaptive light sheet microscope, developed in our group in the framework of the ERC project. In this aspect, our development relates to ordinary microscope system in the same way as “fly by wire” airplane relates to an old-fashioned one.
Our contribution in the development of instrumentation for biomedical research will bring a positive impact on our knowledge about the nature and ourselves, the quality of life and life expectation of the population. Our proposal addresses the largest societal challenge of Europe: the healthcare. Our instrument will contribute to the understanding of complex diseases and support the greying population to stay healthy and self-supportive for extended period of time.
Summary
The project has a goal of starting up a small business producing highly special customizable microscope systems for biomedical research. Microscopic imaging is one of the major drivers of the progress in biomedical and life sciences. The development of novel concepts, addressing the challenges of advanced optical microscopy, represents the front line of scientific research. Modern microscopes are not purely optical devices anymore. They have developed into complex integrated systems, combining optics, mechanics, electronics, feedback control systems, and image processing Many novel concepts of modern microscopy, while very interesting for research, still have to prove the commercial profitability. Such developments can be effectively addressed by start-up companies with a goal of either custom development, production and service of these advanced systems, or development and selling the IP to a larger player.
The major goal of this proposal is the creation of the first commercial optical microscope, the performance of which depends completely on the adaptive optics feedback controls. To prove the feasibility of this approach, we select a highly attractive technical concept of adaptive light sheet microscope, developed in our group in the framework of the ERC project. In this aspect, our development relates to ordinary microscope system in the same way as “fly by wire” airplane relates to an old-fashioned one.
Our contribution in the development of instrumentation for biomedical research will bring a positive impact on our knowledge about the nature and ourselves, the quality of life and life expectation of the population. Our proposal addresses the largest societal challenge of Europe: the healthcare. Our instrument will contribute to the understanding of complex diseases and support the greying population to stay healthy and self-supportive for extended period of time.
Max ERC Funding
149 998 €
Duration
Start date: 2017-05-01, End date: 2018-10-31
Project acronym ALGOA
Project Novel algorithm for treatment planning of patients with osteoarthritis
Researcher (PI) Rami Kristian KORHONEN
Host Institution (HI) ITA-SUOMEN YLIOPISTO
Call Details Proof of Concept (PoC), PC1, ERC-2016-PoC
Summary Osteoarthritis (OA) is a common joint disease affecting over 40 million Europeans. Most common consequences of OA are pain, disability and social isolation. What is alarming, the number of patients will increase 50% in developed countries during the next 20 years. Moreover, the economic costs of OA are considerable since 1) direct healthcare (hospital admissions, medical examinations, drug therapy, etc.) and 2) productivity costs due to reduced performance while at work and absence from work have been estimated to be between 1% and 2.5% of the gross domestic product (GDP) in Western countries.
We have developed an algorithm that is able to predict the progression of OA for overweight subjects while healthy subjects do not develop OA. When employed in clinical use, preventive and personalised treatments can be started before clinically significant symptoms are observed. This marks a major breakthrough in improving the life quality of OA patients and patients prone to OA. Our discovery will directly lead to longer working careers and lesser absence from work, and will result subsequently increased productivity. Moreover, the patients are expected to live longer due to reduced disability and social isolation.
Moreover, the discovery provides economic long-term relief for the health care system, which is burdened by increasing geriatric population and stringent economic environment. With our tool, as an example, by eliminating 25% of medical examinations annually due to overweight or obesity in Finland (150.000 patients), we estimate to decrease annual direct costs by 140M€ and indirect costs by 185M€.
In the PoC project we will carry out technical proof-of-concept and perform pre-commercialisation actions to shorten the time to market. The ultimate goal after the project is to develop our innovation towards a software product, aiding the OA diagnostics in hospitals and having commercialisation potential amongst medical device companies.
Summary
Osteoarthritis (OA) is a common joint disease affecting over 40 million Europeans. Most common consequences of OA are pain, disability and social isolation. What is alarming, the number of patients will increase 50% in developed countries during the next 20 years. Moreover, the economic costs of OA are considerable since 1) direct healthcare (hospital admissions, medical examinations, drug therapy, etc.) and 2) productivity costs due to reduced performance while at work and absence from work have been estimated to be between 1% and 2.5% of the gross domestic product (GDP) in Western countries.
We have developed an algorithm that is able to predict the progression of OA for overweight subjects while healthy subjects do not develop OA. When employed in clinical use, preventive and personalised treatments can be started before clinically significant symptoms are observed. This marks a major breakthrough in improving the life quality of OA patients and patients prone to OA. Our discovery will directly lead to longer working careers and lesser absence from work, and will result subsequently increased productivity. Moreover, the patients are expected to live longer due to reduced disability and social isolation.
Moreover, the discovery provides economic long-term relief for the health care system, which is burdened by increasing geriatric population and stringent economic environment. With our tool, as an example, by eliminating 25% of medical examinations annually due to overweight or obesity in Finland (150.000 patients), we estimate to decrease annual direct costs by 140M€ and indirect costs by 185M€.
In the PoC project we will carry out technical proof-of-concept and perform pre-commercialisation actions to shorten the time to market. The ultimate goal after the project is to develop our innovation towards a software product, aiding the OA diagnostics in hospitals and having commercialisation potential amongst medical device companies.
Max ERC Funding
150 000 €
Duration
Start date: 2018-01-01, End date: 2019-06-30
